# Evaluation of lung epithelial lining fluid concentrations of lascufloxacin against Streptococcus pneumoniae in a hollow-fiber infection model

## TL;DR

Lascufloxacin reaches high concentrations in lung fluid, making it effective against Streptococcus pneumoniae, including drug-resistant strains.

## Contribution

Demonstrates that lascufloxacin's high epithelial lining fluid concentrations are bactericidal against S. pneumoniae using a Hollow-Fiber Infection Model.

## Key findings

- LSFX achieves more than 15 times higher concentrations in ELF compared to blood.
- LSFX shows bactericidal efficacy against both levofloxacin-sensitive and -resistant S. pneumoniae.
- Elevated ELF concentrations of LSFX are critical to its antibacterial activity.

## Abstract

Lascufloxacin (LSFX) achieves concentrations in epithelial lining fluid (ELF) that are more than 15 times higher than those in the bloodstream, making it a promising candidate for respiratory and otorhinolaryngological infections. These concentrations were replicated using the Hollow-Fiber Infection Model and demonstrated bactericidal efficacy of LSFX against levofloxacin-sensitive and -resistant Streptococcus pneumoniae. The study confirms that LSFX’s elevated concentration in ELF plays a significant role in its bactericidal activity.